Abstract
PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors.
Original language | English (US) |
---|---|
Pages (from-to) | 451-458 |
Number of pages | 8 |
Journal | Cancer Drug Resistance |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - 2022 |
Keywords
- PARP inhibitors
- maintenance therapy
- niraparib
- olaparib
- ovarian cancer
ASJC Scopus subject areas
- Cancer Research
- Pharmacology (medical)